|Bid||29.05 x 800|
|Ask||29.08 x 3200|
|Day's Range||28.65 - 29.24|
|52 Week Range||20.10 - 48.40|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 02, 2020 - Feb 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.38|
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice® CDx test to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with GSK’s PARP inhibitor Zejula® (niraparib). “The myChoice CDx test provides valuable molecular insights into tumors and helps identify women with ovarian cancer who are most likely to benefit from PARP inhibitors,” said Nicole Lambert, president, Myriad Oncology.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis® CDx test as a companion diagnostic to AstraZeneca’s (LSE/OMX Nordic/NYSE: AZN) and Merck’s PARP inhibitor Lynparza® (olaparib) for men with metastatic castration-resistant prostate cancer.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Thomas P. Slavin, M.D., FACMG, DABMD, senior vice president of Medical Affairs at Myriad Oncology effective March 2, 2020. In this role, Dr. Slavin will provide medical and scientific leadership across Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Dr. Slavin will report to Nicole Lambert, president of Myriad Oncology.
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
SALT LAKE CITY, Jan. 06, 2020 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that Mark C. Capone, president and.
Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item Hamilton Depression Rating Scale (HAM-D6) was published online in BMC Psychiatry. The key finding is the HAM-D6 scale identified statistically significant improvements in all three clinical endpoints – remission, response and symptoms – between GeneSight®-guided care and treatment-as-usual at Week 8 (Figure 1).
Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.
Shares of Myriad Genetics initially popped Monday after the Food and Drug Administration approved the company's genetic test, dubbed BRACAnalysis CDx, for pancreatic cancer patients.
The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics Inc. ("Myriad" or the "Company") (NASDAQ: MYGN). The investigation relates to possible breaches of fiduciary duty by certain officers and directors of the Company.
Wall Street is set for a sleepy open Monday with stock futures indicating modest gains across all three indexes. The Dow Jones Industrial Average, S&P 500 and Nasdaq Compositewere all set to open up 0.1% as of 8:20 a.m. in what is expected to be a quiet day for trading. (AZN) (ticker: AZN) and (MRK) (MRK) were up 0.6% and 0.2%, respectively, after Lynparza, the ovarian-cancer drug they market, won approval by the Food and Drug Administration to be used to treat advanced pancreatic cancer.
Share of Myriad Genetics Inc. shot up 8.3% in premarket trading Monday, after the molecular diagnostics company said its BRACAnalysis CDx was approved by the Food and Drug Administration as a companion test to identify patients with metastatic pancreatic cancer, who are candidates for treatment with Lynparza. BRACAnalysis CDx is the only FDA-approved genetic test for this indication. Lynparza is marketed by AstraZeneca PLC and Merck & Co. Inc. . "The approval of the BRACAnalysis CDx test for patients with pancreatic cancer highlights our shared vision and long-standing collaboration with Myriad to advance precision medicine for patients in need of new treatments," said Ruth March, head of precision medicine at AstraZeneca. Myriad Genetics's stock has lost 7.9% year to date through Friday, while the S&P 500 has gained 29%.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic test by healthcare professionals to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor Lynparza® (olaparib). Lynparza is marketed by AstraZeneca (LSE/OMX Nordic/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada.
The Food and Drug Administration approves BRACAnalysis CDx, Myriad Genetics' metastatic pancreatic cancer diagnostic tool for patients who are eligible for treatment with Lynparaza, a drug marketed by AstraZeneca.
It hasn't been the best quarter for Myriad Genetics, Inc. (NASDAQ:MYGN) shareholders, since the share price has fallen...
Over the weekend, Myriad was the subject of a Wall Street Journal report that profiled a woman who had her ovaries and fallopian tubes removed after a genetic test showed a heightened risk of cancer. Years later, the woman learned that an updated interpretation of the lab results showed that the specific mutation may not be linked to an increase in cancer risk.
Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that board member S. Louise Phanstiel has been named to WomenInc. “We congratulate Louise for this well-deserved acknowledgment of her leadership and many contributions to our success,” said Mark C. Capone, president and CEO of Myriad Genetics.
Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that results of a new validation study of the company’s polygenic risk score (PRS) for breast cancer were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Tx. The key finding is that the PRS significantly improves the precision and accuracy of breast cancer risk estimates for women of European ancestry who have pathogenic variants (PV) in high- and moderate-penetrance breast cancer genes.
Is Tri Pointe Group Inc (NYSE:TPH) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market […]
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
Shares of Myriad Genetics dropped 3% in premarket trading after the diagnostics maker said its Prequel prenatal screening test is better than non-DNA tests at identifying chromosomal abnormalities in pregnant women with a high body mass index. The study's results were published in the journal Prenatal Diagnosis. Myriad said that Prequel, which uses whole-genome sequencing, can help reduce the need for expensive procedures like amniocentesis or chorionic villus sampling. Sales of its prenatal business, which makes up about 12% of total revenues, rose 5% to $23.5 million in the most recent quarter, up from $18.1 million in the same period a year ago. Myriad's stock has tumbled 14% year-to-date. The S&P 500 is up 24%.
Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis. The key finding is that Prequel is superior to traditional non-DNA screening for identifying chromosomal abnormalities in pregnant women, including those with high body mass index (BMI). The Prequel Prenatal Screen uses a proprietary whole genome sequencing (WGS) approach to identify chromosomal abnormalities including trisomy 21, trisomy 18 and trisomy 13.